New from Hobart and our companies

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017

Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]

Read more

Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe

Stuttgart, Germany, November 15 2016

Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are symptomatic despite appropriate medical therapy…

Read more

Impulse Dynamics Recognized with Frost & Sullivan’s 2016 New Product Innovation Award

Stuttgart, Germany, September 12 2016

Impulse Dynamics, developer of the Optimizer™ IVs implantable device for the treatment of Chronic Heart Failure (CHF), is the recipient of the prestigious Frost & Sullivan 2016 European Chronic Heart Failure Therapy New Product Innovation Award.

Read more

Motorika’s ReoGo’s Effectiveness Demonstrated by Post-Stroke Rehabilitation Study

June 09, 2016

Data from a prospective multicenter, randomized, open, blinded end-point, exploratory clinical trial examining robotic therapy combined with standard upper extremity therapy in patients recovering form stroke was published in the March issue of the American Heart Association’s Stroke journal…

Read more

Impulse Dynamics Completes $30 Million Financing Round

Mt. Laurel, New Jersey, May 13 2016

Impulse Dynamics, developer of the Optimizer™ IVs implantable device for treatment of chronic heart failure (CHF), announced today that the company has closed a $30 million financing round…

Read more

Going red to raise awareness of heart disease in women

Mt. Laurel, New Jersey, February 3 2017

Friday February 3rd saw women and men across the United States dressed in shades of red, from scarlet to crimson, for National Wear Red Day.

Read more

Spinal injury patient learns to walk again with Motorika’s ReoAmbulator

October 18, 2016

Motorika’s pioneering lower limb robotic rehabilitation system, the ReoAmbulator, is already changing the lives of patients in the US suffering from neurological and orthopedic disorders. NHC HealthCare, Clinton recently reported its successful experience with the first system to be installed in the US…

Read more

Promising Results from Molecular Dynamics’ CZT Based Digital SPECT/CT Trial

August 24, 2016

Molecular Dynamics has successfully completed the first phase of a clinical trial to evaluate the Valiance X12 whole-body Cadmium Zinc Telluride (CZT) based digital SPECT/CT prototype with promising results. The study, conducted at the Chaim Sheba Medical Center in Israel, was designed to assess the image quality and diagnostic performance of the Valiance X12 and demonstrated improved image resolution and contrast.

Read more

Renal Dynamics Commences TREAT-HTN Clinical Study for the Treatment of Uncontrolled Hypertension

Zug, Switzerland, May 17 2016

Renal Dynamics has successfully treated the first patient in its TREAT-HTN prospective, post-marketing multi-center European clinical study to evaluate the safety and efficacy of its third-generation Renal Denervation (ReDy™) System.

Read more

EPD Meets Another Significant Milestone, Completing Its First Human Experience

Tortola, April 28 2016

EPD has completed its first human procedure, having successfully tested its revolutionary D700 Dielectric Sensing System…

Read more

Randomization of the FIX-HF-5C Confirmatory Study Completed

Orangeburg, New York, March 31, 2017

Impulse Dynamics is pleased to announce that it has successfully completed enrollment of the 160 subjects required for its FIX-HF-5C Confirmatory Study. The FIX-HF-5C Study is a prospective, multicenter, randomized study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable Optimizer System in patients with NYHA class III […]

Read more

Going red to raise awareness of heart disease in women

Mt. Laurel, New Jersey, February 3 2017

Friday February 3rd saw women and men across the United States dressed in shades of red, from scarlet to crimson, for National Wear Red Day.

Read more

Impulse Dynamics Successfully Launches the Optimizer Smart Device for Heart Failure Treatment in Europe

Stuttgart, Germany, November 15 2016

Impulse Dynamics has launched the next generation of its Optimizer device, the Optimizer Smart, in Europe after it received the CE mark. The Optimizer Smart is a minimally invasive implantable device designed to treat chronic heart failure (CHF) in patients that are symptomatic despite appropriate medical therapy…

Read more

Spinal injury patient learns to walk again with Motorika’s ReoAmbulator

October 18, 2016

Motorika’s pioneering lower limb robotic rehabilitation system, the ReoAmbulator, is already changing the lives of patients in the US suffering from neurological and orthopedic disorders. NHC HealthCare, Clinton recently reported its successful experience with the first system to be installed in the US…

Read more

Impulse Dynamics Recognized with Frost & Sullivan’s 2016 New Product Innovation Award

Stuttgart, Germany, September 12 2016

Impulse Dynamics, developer of the Optimizer™ IVs implantable device for the treatment of Chronic Heart Failure (CHF), is the recipient of the prestigious Frost & Sullivan 2016 European Chronic Heart Failure Therapy New Product Innovation Award.

Read more

Promising Results from Molecular Dynamics’ CZT Based Digital SPECT/CT Trial

August 24, 2016

Molecular Dynamics has successfully completed the first phase of a clinical trial to evaluate the Valiance X12 whole-body Cadmium Zinc Telluride (CZT) based digital SPECT/CT prototype with promising results. The study, conducted at the Chaim Sheba Medical Center in Israel, was designed to assess the image quality and diagnostic performance of the Valiance X12 and demonstrated improved image resolution and contrast.

Read more

Motorika’s ReoGo’s Effectiveness Demonstrated by Post-Stroke Rehabilitation Study

June 09, 2016

Data from a prospective multicenter, randomized, open, blinded end-point, exploratory clinical trial examining robotic therapy combined with standard upper extremity therapy in patients recovering form stroke was published in the March issue of the American Heart Association’s Stroke journal…

Read more

Renal Dynamics Commences TREAT-HTN Clinical Study for the Treatment of Uncontrolled Hypertension

Zug, Switzerland, May 17 2016

Renal Dynamics has successfully treated the first patient in its TREAT-HTN prospective, post-marketing multi-center European clinical study to evaluate the safety and efficacy of its third-generation Renal Denervation (ReDy™) System.

Read more

Impulse Dynamics Completes $30 Million Financing Round

Mt. Laurel, New Jersey, May 13 2016

Impulse Dynamics, developer of the Optimizer™ IVs implantable device for treatment of chronic heart failure (CHF), announced today that the company has closed a $30 million financing round…

Read more

EPD Meets Another Significant Milestone, Completing Its First Human Experience

Tortola, April 28 2016

EPD has completed its first human procedure, having successfully tested its revolutionary D700 Dielectric Sensing System…

Read more

About Hobart Group

The Hobart Group develops and commercializes medical technologies which target top healthcare markets with significant unmet needs.  Its growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information, visit www.Hobart-Group.com.

Media kit

Journalists and reporters are welcome to use the following materials related to Hobart Group

For media inquiries

Mrs. Sharon Alon
Email: Media@Hobart-Group.com
Tel: +1 347-566-6113

Stay up to date